Building A Biotech Rebound

A slow start and a dearth of mergers and acquisitions made 2016 a tough year for biotech, but new gene and immuno-therapies are leading the way for a much stronger performance when 2017 results are in.

By the BF Staff 
From the May/June 2017 Issue

Investing in biotech is a higher risk venture, but after the volatility of 2016 the sector is showing some signs of recovery. The Nasdaq Biotech Index collapsed 28 percent in the opening weeks of 2016, ending the year down about 22 percent. A contributing factor to this decline was a slowdown in large mergers and acquisition in a sector that needs deal speculation to boost the share prices of companies years away from actually marketing a drug.

Some of the uncertainty that limited the number of deals last year remains, but the fundamentals are strengthening. Big Pharma constantly needs drug candidates to replace failed projects and expired patents, and this is fueled by the growth of biotech startups. A recent Deloitte study found the R&D productivity of 12 of the biggest biopharma companies, measured by expected return, hit a seven-year low at the end of next year.

M&A in 2016 involved 326 deals worth about $91 billion, down from $118 billion in 2015 (326 deals marked the lowest number of deals in six years). Shire’s purchase of Baxalta accounted for more than a third of the total deal spending in 2016.

However, momentum to get deals done is building in 2017. More than a dozen biopharma firms had more than $220 billion in cash and marketable securities on hand at the end of the third quarter.

Sluggish near-term sales growth adds to the motivation for many firms to act. Johnson & Johnson, Amgen Inc., and Gilead Sciences Inc. have the most M&A-friendly combination of cash and sales growth. But there are many other industry leaders poised to make big moves.

New products are on the way: the immuno-therapy market is expanding exponentially, with cancer vaccines entering clinical trials and some nearing commercialization. PD-1 inhibitors are starting to be approved for treating various cancers.”

Gene therapies are also getting closer to market. Spark Therapeutics could have the first approved in the United States as soon as next year. Meanwhile, the revolutionary gene editing technique CRISPR-Cas 9 is finally in human trials.


Kentucky may be better known for its reputation in the bourbon and automotive industries, but the commonwealth also has established a growing presence in the biotech and medical devices sectors that cannot be ignored.

Dr. Ray Takigiku, CEO and founder of Bexion Pharmaceuticals, received Food and Drug Administration approval last year to begin phase-one clinical trials on his company’s anti-cancer drug BQX-350. Based in Covington KY, Bexion is a privately held biotech company focused on the development and commercialization of innovative cures for cancer. (Photo: Kentucky Cabinet for Economic Development)

Hera BioLabs Inc. is a prime example of this growth. When Hera announced its new headquarters in Lexington last year, it did more than simply add 23 new jobs and invest $1.8 million; it demonstrated Kentucky’s capacity to support innovative companies.

“Kentucky is an ideal location for a contract research organization like Hera to start and grow as it offers a competitive edge in manufacturing, and an excellent place to recruit and attract the type of talent we are looking for,” said Jack Crawford, Hera CEO.

Hera was originally part of another company and relocated from a site at the University of Kentucky (UK) to an existing facility. The new space was constructed to support the development of specialized laboratory rat models, which are expected to make pharmaceutical testing quicker, safer and more cost effective.

Also in 2016 in Lexington, India-based Piramal Pharma Solutions announced an investment of $10 million to expand Coldstream Laboratories Inc., a company that had spun off as a private company of UK’s Research Foundation. The move came only one year after Piramal, a global leader in pharmaceutical contract services, purchased Coldstream Labs.

In keeping with the trend, MobileMedTek, an ISO-certified medical device company, recently announced plans to invest nearly $5.6 million and create 50 full-time jobs to renovate and expand its operation in Louisville to better serve new innovators and entrepreneurs. The company, which develops new tools for the neurodiagnostic industry, has been located in Louisville since 2010.

Bexion Pharmaceuticals LLC in the Northern Kentucky community of Covington has grown an accidental discovery by a scientist at Cincinnati Children’s Hospital Medical Center into a unique approach to treating cancer that is now in clinical trials.

Since locating in Kentucky in 2006, Bexion has received matching funding from the commonwealth to support various stages of grant awards from the SBIR/STTR program.

Dr. Ray Takigiku, president and CEO of Bexion, acknowledged the company’s role as a catalyst for Covington’s high-tech industry synergies, including the bioLogic incubator, co-founded by Takigiku as a consulting organization, as well as UpTech Inc., a technology accelerator program that works with up to 10 startups each year and provides up to $50,000 per company.

In addition to industry synergies, a Kentucky location also offers firms an affordable place to conduct business and a climate that encourages growth.

“Our office building is located in a neighborhood, essentially,” Takigiku said. “People are out walking dogs. Great restaurants are within walking distance, and I can walk to work.”

When Bexion relocated to Kentucky from Ohio, the company discovered the region’s friendly, yet driven personality. The same can be said for officials at Catalent Pharma Solutions in Winchester.

The global company has worked closely with the Kentucky Cabinet for Economic Development on initiatives such as incentives to support hiring, and made connections to university partners and veteran’s hiring programs to build its talent base.

“Active leadership can take many forms, but from our perspective, when we have a need or if we need to make a connection, the answer from the team at the Cabinet is always, ‘How can we help? Let’s go get this done,’” according to Catalent’s communications department. “Looking back on our growth, it is clear that the support and partnership with the Kentucky Cabinet for Economic Development has been a clear contributor.”

Catalent’s facility in Winchester, in Eastern Kentucky, is one of the pharmaceutical industry’s premier sites for advanced oral controlled-release drug formulation manufacturing, with integrated analytical and development services. The site is poised to play a long-term role in the production of customer Pfizer Inc.’s over-the-counter Nexium 24HR heartburn treatment.

The operation stands as an example of Kentucky’s ability to support the medical and pharmaceutical industries through long-term success. From pharmaceuticals to medical devices to biotech, Kentucky has become home to a growing number of high-tech companies as they witness the success of their peers in the state. Over a two-year period, Catalent finished one expansion and started another. The total investment is expected to exceed $114 million and add 450 jobs. Since 1992, Catalent’s Winchester operation has launched more than 100 products for its pharmaceutical and consumer health customers.

Apellis Pharmaceuticals moved to Crestwood, south of Louisville, in 2010, and currently has three clinical programs underway in rare diseases, ophthalmology and pulmonology, according to Apellis CEO Dr. Cedric Francois.

One drug is a subcutaneous injection to correct the underlying immune dysfunction in rare diseases, which is in Phase II trials and expects to enter Phase III trials in September.

In December 2016, Apellis was awarded a fast-track designation by the FDA for its treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease.

Apellis has co-located three ventures at its office in Crestwood. Of note is an IT platform to track in real time how patients benefit from certain drug treatments. According to Francois, the data ties into “pricing models, reimbursement models, disease management, health economics and population.”

From pharmaceuticals to medical devices to biotech, Kentucky has become home to a growing number of high-tech companies as they witness the success of their peers in the state. With the commonwealth’s business-friendly environment and emphasis on growth, the question is when, not if, the next innovative health care company locates in Kentucky.


When most people think of South Florida, images of sand and surf typically come to mind. Lesser known is that Greater Fort Lauderdale is home to one of the most dynamic biotechnology and pharmaceutical industry clusters in the country. The region currently holds 1,500 bioscience institutions that employ more than 26,000 people and generate $4 billion in revenue each year.

There are several reasons why Greater Fort Lauderdale provides a stimulating and supportive business environment for biotech start-ups, midsize medical manufacturers and global pharmaceutical companies. Chief among them are access to leading academic institutions with 35 colleges and universities based in the region; a large, diverse, multilingual workforce that totals six million people; direct connections to Latin American and Europe; and zero state income tax.

Apotex, Lupin, Stryker, Teva and Trividia Health are among the major medical device, biotechnology and pharmaceutical companies that have chosen to base their research & development, manufacturing and distribution facilities in Broward County.

South Florida’s universities, research parks and economic development organizations have joined together to form Life Sciences South Florida (LSSS), an organization that works to connect biotechnology companies with venture capital and academic institutions that will accelerate their research commercialization. LSSS also supports local talent development by enhancing K-20 STEM education.

On a statewide level, BioFlorida is the voice of Florida’s life sciences industry with regional chapters that represent nearly 5,500 establishments and research organizations in the biotechnology, pharmaceuticals, medical devices/diagnostics and bio-agriculture sectors. BioFlorida’s initiatives provide a strong business climate for the advancement of innovative products that improve lives and promote economic benefits to the state.

Additionally, the Florida Institute for the Commercialization of Public Research facilitates the creation of spin-off companies from technology developed at Florida’s publicly funded research institutions. The institute provides support services, including building relationships with seasoned entrepreneurs, in order to hasten the growth of commercially viable discoveries.

More than 200 research projects are currently underway at Nova Southeastern University (NSU), including studies on cardiovascular disease, anti-cancer therapies, chronic fatigue syndrome, autism, coral reef restoration, stem cells and wildlife DNA forensics, among other subjects.

NSU’s Center for Collaborative Research (CCR) opened in September 2016 as one of the largest and most advanced research facilities in Florida. The center features leading research equipment, including access to a high-performance computing environment, and other resources, such as Florida LambdaRail, a high-speed broadband service delivery network.

Housed in the CCR, NSU’s Technology Incubator enables qualified companies to lease private space (up to 60,000 square feet) that will give them access to researchers, technology and labs. The CCR includes several core facilities, including a Genomics Core Facility for sequencing human genes associated with disease, Flow Cytometry Core Facility for isolating special cell types such as immune and stem cells, Cell Therapy Core Facility for developing immunotherapies and regenerative medicines and an Imaging Core Facility with advanced digital microscopy capabilities.

NSU also has established several research institutes and centers that address some of today’s most pressing issues by using a multidisciplinary, inter-professional approach. Housed in the CCR, these centers include NSU’s AutoNation Institute for Breast and Solid Tumor Cancer Research, NSU Cell Therapy Institute (a partnership with researchers from Karolinska Institutet in Sweden), NSU’s Institute for Neuro-Immune Medicine, NSU’s Rumbaugh-Goodwin Institute for Cancer Research and NSU’s Emil Buehler Research Center for Engineering, Science and Mathematics.

NSU’s College of Osteopathic Medicine serves the region with a variety of clinical and research programs. For example, NSU’s Institute for Neuro-Immune Medicine treats patients with conditions such as chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), Gulf War Illness (GWI) and other neuro-immune conditions, and conducts basic and clinical research in this field.

Leading biotechnology companies and medical manufacturers that operate out of Greater Fort Lauderdale/Broward County currently include:

  • Apotex: a leading Canadian-owned pharmaceutical company that recently announced a $184 million expansion plan, which will include the development of a new research center and manufacturing facility in Miramar.
  • Allergan: a brand/generic pharmaceutical company formerly known as Actavis. The company’s pharmaceutical manufacturing and warehousing facility in Davie manufactures over 2 billion units annually.
  • Lupin Pharmaceuticals: a pharmaceutical research company based out of India, recently announced plans to expand its operations in Coral Springs and open a new laboratory by the end of 2017. The company’s senior vice president stated that “the ability to recruit top scientists in South Florida” was a driving factor in locating the research center in Broward County.
  • Bolton Medical: located in Sunrise, develops new products for endovascular aortic treatment. One of Bolton’s products is its Relay Thoracic Stent-Graft with Plus Delivery System, a life-saving technology offered to patients with Thoracic Aortic Aneurysms. It allows surgeons to achieve a more satisfactory placement of the stent graft on a range of different patients.
  • Goodwin Biotechnology, Inc: a fully integrated contract manufacturing organization (CMO) of monoclonal antibodies and recombinant proteins for preclinical and phase I/II/III clinical trials.
  • • Hema Diagnostic Systems, LLC: a Miramar-based company that produces a full line of rapid diagnostic assays for major infectious disease testing (for export only).
  • ImmunoSite Technologies, LLC (IST): a Miramar-based provider of automation, design and customization of complex biological assays to biotechnology and pharmaceutical industries worldwide.
  • Stryker Mako: a medical device company in Davie that markets its RIO® Robotic-Arm Interactive Orthopedic system and its proprietary RESTORIS® implants for minimally invasive orthopedic knee procedures.
  • OmniComm Systems, Inc.: a Fort Lauderdale-based global provider of eclinical solutions.
  • OrbusNeich: a medical device company that develops therapies for vascular disease at its Advanced Research and Development facility in Fort Lauderdale.
  • SHL Pharma: recently expanded its manufacturing and R&D facility in Deerfield Beach. SHL Pharma is part of SHL Group, the world’s largest privately owned designer, developer and manufacturer of advanced drug delivery systems.
  • Trividia Health: a subsidiary of China-based Sinocare Group has a large facility in Fort Lauderdale that makes glucose-monitoring equipment and related products for diabetics.
  • U.S. Stem Cell Inc: located in Sunrise, has multiple cell therapies in various stages of development that repair tissues damaged by injury or disease.


This spring, the University of Iowa (UI), a major medical research institution in Iowa City, is implementing or partnering on three new initiatives, each of which will support the state’s surging medical device and equipment industry: new co-lab space, an advanced prototyping studio and early-stage incubators.

The BioVentures Center at the University of Iowa provides life sciences startups with a wet lab and office space. It’s part of a multi-stage incubation system at the university that will be expanding this spring. (Photo: University of Iowa)

Iowa is in the midst of a medical device and equipment boom. Statewide employment in the medical device and equipment sectors grew more than 35 percent between 2012 and 2014 (the most recent years for which data is available), according to the Biotechnology Innovation Organization. This growth is being driven by the UI and its Carver College of Medicine, a U.S. News & World Report top 15 public medical school, which received almost $230 million in external funding in FY16.

The university, the Iowa Economic Development Authority and the Iowa City Area Development Group are excited to support these three new initiatives:

The co-lab space, set to open in spring-summer 2017, will be called MERGE. To enhance visibility of the project, it will be located on Iowa City’s downtown pedestrian mall, the city’s main shopping and entertainment area. MERGE will provide a collaborative environment for UI faculty and students, as well as local tech entrepreneurs, to code, prototype and build tech companies. There will be dedicated offices for faculty and 3D printers for prototyping.

Equipment and support for advanced prototyping, called protostudios, will be co-located within MERGE, with additional space in the university’s physics building. This dry lab for advanced prototyping and machining is being overseen by Neil Quellhorst, a veteran engineer and university instructor with a nearly 40-year career, including positions at Honeywell and Rockwell Collins, as well as small, entrepreneurial companies. Acting in a “shop teacher” type role, with support by 3D Design Prototype Director Chuck Romans, Quellhorst will set up, support, and train entrepreneurs on state-of-the-art, rapid-prototyping fabrication equipment. Protostudios will provide local entrepreneurs a place to design and manufacture electronic devices to secure development funding.

A counterpart to the “dry lab” space offered by protostudios, the UI recently opened wet lab space as an early-stage incubator called the Translational Research Incubator (TRI), which is located on the UI healthcare campus in the Medical Laboratories building. All four spots in the space already are occupied by faculty developing startups. And because the space is co-located with the university’s instructional laboratories, faculty can easily “switch hats” and move from their university research to their entrepreneurial research. TRI provides entrepreneurs up to a year to thoroughly assess their IP and develop proofs of concept. It’s designed to serve as the earliest stage in UI’s multi-stage incubator system.

University economic development staff will identify prospective tenants and users for the dedicated university spaces within MERGE and provide early-stage tech transfer support for faculty who have research that shows promise of being developed into inventions, treatments, services or startup ventures. Tenants will have a defined period of time to conduct market analyses, create prototypes, develop plans for raising initial funding and—if viable—explore moving to larger space—potentially the UI Research Park—as a startup.

Each of these new initiatives will complement the incubation infrastructure already in place at UI. Completed in 2010, the 35,000-square-foot BioVentures Center at the UI Research Park provides life science startups dry and wet lab, as well as office space. The BioVentures Center is currently at 100 percent capacity with 17 life science companies employing 90 people. The nearby Technology Innovation Center offers approximately 40 additional offices and suites for lease to engineering and technology-based tenants who do not require wet lab space.

Over the past 30 years, UI has spun more than 100 companies out of its incubator infrastructure, and provided research and research infrastructure to countless private life science enterprises. The country’s largest, and longest-running, university-affiliated, FDA-registered pharmaceutical manufacturing facility is UI Pharmaceuticals, and the UI Center for Biocatalysis and Bioprocessing has been providing advanced research in the biocatalytic sciences to companies since 1982.

These three new initiatives—MERGE, protostudios and TRI —add increased medical device resources to an already rich life science portfolio available from the University of Iowa. With the other business advantages of locating in Iowa, including one of the nation’s lowest costs of doing business, Iowa is positioning itself for many more years of double digit growth in its medical device industry.

To learn more about what the UI is doing to support medical device companies, contact the University of Iowa Office of Research and Economic Development at (319) 335-2328 or To read more about the advantages of doing business in Iowa, as well as state programs available to businesses, visit


After years of aggressive, coordinated efforts, Florida has firmly established itself as a true hub for the life sciences. Today, the state is home to some of the nation’s most highly regarded research centers and more than 1,200 biotech, pharmaceutical and medical devices companies. Florida has the science, talent and support structure biotechs need to succeed.

Florida Gov. Rick Scott cuts the ribbon at the grand opening of Johnson & Johnson’s Global Services Center in Tampa. (Photo: Florida EOG)

Last fall, global healthcare leader Johnson & Johnson celebrated the grand opening of its new Global Services Center in Tampa. More than 250 employees already work in the $23 million, 88,500-square-foot facility, and an additional 250 professionals will be hired over the next three years.

The new Global Services Center is part of a broader network of Johnson & Johnson centers that are designed to handle work for its operating companies in the areas of finance, human resources, information technology and procurement.

Dominic Caruso, Johnson & Johnson’s Chief Financial Officer, discussed the importance of workforce as a major reason for selecting Tampa. “Last year, almost one-quarter of Johnson & Johnson’s new hires were young professionals under the age of 35. Tampa provides a great source of managerial-level talent due to the presence of other shared service providers in the community.”

More than 27,000 Floridians work in the state’s biotechnology, pharmaceutical manufacturing and medical device manufacturing industries, and the state’s universities are among the nation’s top producers of STEM graduates.

Florida is ranked 2nd among states for FDA registered medical device manufacturing facilities. Nearly 19,000 Floridians work in this industry, with a majority of companies located along the I-4 Corridor in Central Florida, the Jacksonville area and in South Florida.

Arthrex has been based in Naples, Florida since 1991. Over the last 25 years, the company has grown into a global leader in arthroscopic surgery, developing more than 9,500 innovative products and surgical procedures to advance minimally invasive orthopedics worldwide. The company trains thousands of surgeons annually at its medical education facility in Naples.

Last summer, Arthrex announced it will expand in North Naples, creating 560 jobs and investing more than $63 million in Collier County. The company already employs more than 2,200 Floridians.

Reinhold Schmieding, President and Founder of Arthrex, said, “Arthrex is committed to reinvesting in our community, and the best investment is growing our business right here in Southwest Florida. This investment will help us expand our research, manufacturing product development and medical education to help improve the lives of people in Southwest Florida with our company and around the world with our products.”

Florida’s size and workforce pipeline allow it to support strong industry clusters across the state. The KLS Martin Group, a global leader in innovative surgical technology, is establishing its first U.S. manufacturing operations in Jacksonville. KLS Martin Manufacturing will create at least 25 new jobs and invest more than $5 million. The company currently employs more than 150 Floridians.

The company considered a number of cities across the country when deciding on a site for its manufacturing operations. Ultimately, Jacksonville’s competitive location, access to talent and current footprint were key reasons in the company’s decision.

The manufacturing establishment will create high-tech, high-skill manufacturing and engineering jobs to the KLS facility. The focus of the new manufacturing operations will be on precision 3D printing and milling of products for reconstructive surgery.

Tom Johnston, of KLS Martin Manufacturing, said, “The KLS Martin Group is excited to establish its first surgical implant manufacturing company outside of Germany here in Jacksonville. This new company will allow the KLS Martin Group to provide innovative products through cutting edge 3D printing technology that will improve patient care and surgical outcomes.”

Florida’s advanced manufacturing industries are diverse and include sectors producing intermediate and finished products ranging from 3D printing to plastics to aerospace vehicles. In total, Florida is home to over 19,000 manufacturers employing more than 331,000 workers.

In addition to Johnson & Johnson, Arthrex and KLS Martin Manufacturing, life science leaders like Bristol-Myers Squibb, Medtronic, Mazor Robotics, B. Braun and Zimmer-Biomet all have significant operations across the state.

Florida is home to the nation’s second-largest medical device manufacturing industry, third-largest pharmaceuticals manufacturing industry and seventh-largest biotech R&D industry. All of that industry expertise, in a cost-competitive and welcoming state, means that Florida isn’t just ready for the future—we are the future.

To learn more about how Florida can help your biotech business grow, please visit


You may know Madison as the seat of state government, home of the flagship campus of the University of Wisconsin, and a community on the shores of four beautiful lakes with an isthmus framing the heart of the city.

Promega (lab pictured), a global leader in providing innovative solutions to life scientists, has a portfolio of more than 3,000 products spanning the disciplines of genomics, protein analysis, cellular analysis and drug discovery. (Photo: Promega Corporation)

Did you also know the Madison Region had the fourth highest rate of job growth in the country last year, and the second fastest high-tech job growth behind only San Francisco between 2000 and 2015? The region has world-class research facilities, exceptional technical colleges, an absurdly convenient airport and offers easy access to major metro areas.

A hotbed of innovation in the life sciences sector, the Madison Region claims an array of groundbreaking discoveries in biosciences and biotechnology.

From the discovery of vitamins in the early 1900s to the first human embryonic stem cells grown in a laboratory, the Madison Region is an established leader in outstanding biotech research and development. Our life sciences sector is driven largely by UW-Madison, which ranks 6th nationwide for federal research funds with over $1 billion in expenditures, more than half of which is spent directly in life sciences.

Proving that strength in the life sciences is not reserved for the coasts, the Madison Region’s employment in scientific R&D services grew over 190 percent between 2005 and 2015, far outpacing national growth of 14 percent. According to Economic Modeling Specialists International, the bioscience industry directly supported 10,000+ regional jobs in 2015.

From our base in R&D stems a deep concentration of major life science firms—both mature and startup—that have chosen to build headquarters in the Madison Region. Some of the Region’s major life sciences employers include Promega, Covance and Exact Sciences. Support institutions such as BioForward pair with resources for incubation, clinical trials and scientific testing to help biotech discoveries move from the lab to the marketplace.

The 2014 Batelle/BIO report on state bioscience jobs, investments and innovation put Madison at the top of the list among metro areas nationwide when it comes to the strength of its bioscience sector.

The report, which breaks down the bioscience industry into five sectors, ranked the Madison metro area in the top nine for specialized employment concentration in bioscience. Madison also is one of just nine regions with significantly higher than average job concentration in four out of five bioscience sectors.

According to Batelle/BIO, Madison ranked 4th in job creation in the drug and pharmaceuticals sector, employing nearly 2,000 in 2012. It also ranked 8th in nationwide job concentration in medical devices, a sector that also employs about 2,000 in the metro area.

Madison has specialized employment concentration in four out of five bioscience subsectors:

  • Bioscience-related distribution
  • Drugs and pharmaceuticals
  • Medical devices and equipment
  • Research, testing and medical laboratories

This places Madison among the top 9 U.S. metro areas on this measure.

The University of Wisconsin System Schools located in or adjacent to the Madison Region support the region’s strong history and exceptional strength in the life sciences industry. In 2015-16, these system schools granted a combined total of 5,229 life science related degrees.

The UW-Madison campus is leading the way with 3,634 related conferrals.

Degrees and certificates in bioinformatics, biotechnology, horticulture and stem cell technologies are among programs offered at regional technical colleges, while information technology, manufacturing and laboratory technician programs offer supporting and supplementary education for this sector’s workforce.

Leading biotech players located in Madison include:

  • Cellular Dynamics, a FUJIFILM company. Cellular Dynamics is a leading developer and manufacturer of human cells used in drug discovery, toxicity testing, stem cell banking and cell therapy development. The Company partners with innovators from around the world to combine biologically relevant human cells with the newest technologies to drive advancements in medicine and healthier living. Founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research, Cellular Dynamics is based in Madison with a second facility in Novato, California. For more information visit
  • Covance Inc. Covance is a global contract research organization and the world’s most comprehensive drug development company. The company advances healthcare and delivers Solutions Made Real® by providing high-quality nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development. Covance offers laboratory testing services to the chemical, agrochemical and food industries and is a market leader in services such as toxicology, central laboratory and discovery and is a top global provider of Phase III clinical trial management services. For more information visit
  • Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer.
  • Promega. With a portfolio of more than 3,000 products covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity, Promega is a global leader in providing innovative solutions and technical support to life scientists in academic, industrial and government settings. Promega products are used by life scientists who are asking fundamental questions about biological processes as well as by those who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics and use genetics and DNA testing for human identification. For more information visit
  • Stratatech, a Mallinckrodt Company. Stratatech is a regenerative medicine business focused on skin regeneration therapies for severe burns and other rare diseases, as well as chronic non-healing ulcers; it was founded in 2000 to commercialize an extraordinary discovery made at the University of Wisconsin-Madison. The discovery of NIKS® cells—a human keratinocyte cell line that produces living tissue nearly identical to native human skin—has the potential to revolutionize wound care. For more information visit